天津科学技术出版社

B 因子抑制剂治疗重型再生障碍性贫血-阵发性睡眠性血红蛋白尿综合征 1 例

张会勤 ,霍继颖 ,白洁 *
作者信息
  1.  天津医科大学第二医院血液科,天津 300211
*通信作者

摘要

患者男性,62 岁,于 2025 年 2 月因“间断瘀斑1月余,眼痛,头痛 1 周冶入院天津医科大学第二医院。血常规:白细胞1. 47×109/L,中性粒细胞绝对值0. 39×109/L,淋巴细胞百分比 71% ,红细胞1. 08×1012/L,血红蛋白46g / L,血小板3. 00×109/L,网织红细胞百分比0. 15% 。血浆结合珠蛋白(HP)正常(51mg/L),游离血红蛋白(F-HB)降低(<0. 05g/L),尿含铁血黄素阴性,乳酸性脱氢酶(LDH)791U/ L,双部位骨髓形态增生极度减低,骨髓活检增生极度低下,网银染色阴性。 流式细胞术(FCM):红细胞及粒细胞表面的 CD59-和荧光素标记的气单胞菌溶素(FLare)示粒系阵发性睡眠性血红蛋白尿综合征(PNH)克隆 87. 55% 。 全外显子测序:PIGA 基因 6. 45%,确诊为重型再生障碍性贫血-PNH(SAA-PNH),予以环孢素 A(CSA)免疫抑制剂治疗后出现肌酐进行性升高,遂停用 CSA 治疗,使用 B 因子抑制剂盐酸伊普可泮胶囊(200 mg,bid,po)治疗3 个月后,红细胞脱离输注,白细胞正常,F-HB 及 HP 正常,LDH 321 U/ L,双部位骨髓增生活跃, FLare 示粒系PNH克隆7. 76% 。对于 SAA-PNH 患者,应用新型B因子抑制剂可能减轻补体对造血干/祖细胞的攻击,恢复造血,且并不增加 PNH 克隆。

Factor B inhibitor in the treatment of severe aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: a case report

Huiqin ZHANG , Jiying HUO , Jie BAI *
Author Information
  1.  Department of Hematology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
*Corresponding author

Abstract

A 62-year-old male patient was admitted to The Second Hospital of Tianjin Medical University in February 2025 due to " intermittent ecchymoses for more than 1 month, and eye pain, headache for 1 week" . Routine blood test results showed: white blood cell count 1.47×109/L, absolute neutrophil count 0.39×109/L,lymphocyte percentage 71% , red blood cell count: 1. 08×1012/L,hemoglobin 46g/L, platelet count 3. 00×109 / L, and reticulocyte percentage 0. 15% . Plasma haptoglobin (HP) was normal (51mg/L) ,National and free hemoglobin (F-HB) was decreased (<0. 05 g / L), urine hemosiderin (-). Lactate dehydrogenase (LDH) 791 U/ L, bone marrow morphology at two sites showed extremely reduced hyperplasia, bone marrow biopsy revealed marked hypoplasia, and reticulin staining was negative. Flow cytometry (FCM) showed that CD59- on the surface of red blood cells and granulocytes, and fluoresceinlabeled aerolysin (FLare) indicated 87. 55% in granulocyte lineage. Whole-exome sequencing revealed a 6. 45% PIGA gene mutation. The patient was diagnosed with severe aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome (SAA-PNH). Progressive elevation of serum creatinine occurred after treatment with the immunosuppressant cyclosporine A (CSA), so CSA was discontinued.After 3 month of treatment with the Factor B inhibitor iptacopan hydrochloride capsules (200 mg, bid, po), the patient was weaned off red blood cell transfusion, white blood cell count returned to normal, F-HB and HP were normal, LDH 321 U/ L, bone marrow hyperplasia at two sites was active, and FLare showed 7. 76% in granulocyte lineage. For patients with SAA-PNH, the application of novel Factor B inhibitors may alleviate complement-mediated attack on hematopoietic stem/ progenitor cells, restore hematopoiesis, and not increase PNH clones.

再生医学研究 Copyright © 2026. All Rights Reserved